Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Innate Pharma S.A. - American Depositary Shares
(NQ:
IPHA
)
1.470
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Innate Pharma S.A. - American Depositary Shares
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Innate Pharma to Host Virtual KOL Event on Lacutamab
November 27, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update
November 14, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update
November 07, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023
November 03, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Its Participation to Upcoming Investor Conferences
October 27, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma 2024 Financial Calendar
October 19, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Abstracts Selected for ESMO Congress 2023
October 16, 2023
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023
October 09, 2023
From
Innate Pharma SA
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
October 05, 2023
Via
Benzinga
Regulatory Hurdle For Innate Pharma's Blood Cancer Studies
↗
October 05, 2023
The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201...
Via
Benzinga
Innate Pharma Provides Update on Lacutamab Clinical Program
October 05, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023
September 22, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Reports First Half 2023 Financial Results and Business Update
September 14, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update
August 29, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
August 10, 2023
From
Innate Pharma SA
Via
Business Wire
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
July 11, 2023
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023
July 07, 2023
From
Innate Pharma SA
Via
Business Wire
First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
June 26, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
June 16, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
June 12, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
June 10, 2023
From
Innate Pharma SA
Via
Business Wire
Why Shares of Innate Pharma Jumped Thursday
↗
June 08, 2023
The company's collaboration agreement with Sanofi could soon pay off.
Via
The Motley Fool
SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
June 08, 2023
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023
June 07, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
May 26, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
May 23, 2023
From
Innate Pharma SA
Via
Business Wire
Outcome of Innate Pharma’s 2023 Annual General Meeting
May 12, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Reports First Quarter 2023 Financial Results and Business Update
May 10, 2023
From
Innate Pharma SA
Via
Business Wire
Number of shares and voting rights of Innate Pharma as of May 1, 2023
May 09, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Conference Call and Webcast for Q1 Business Update
May 03, 2023
From
Innate Pharma SA
Via
Business Wire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
